HomeHLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8 + T and NK cells: a novel therapeutic tumour vaccine June 1, 2022 print this article HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8 + T and NK cells: a novel therapeutic tumour vaccine Yu et al.; J Hematol Oncol. 2021 Apr 28;14(1):71